Non-Hodgkin's B-cell Lymphoma Clinical Trial
Official title:
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Non-Hodgkin B-cell Lymphoma
This study will treat patients with non-Hodgkin B-cell lymphoma who have relapsed from, refractory or intolerant to prior therapy. This study will help understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Non-Hodgkin B-cell Lymphoma. This study includes dose escalation (Part A) and dose expansion (Part B). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04317885 -
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects
|
Phase 1 | |
Active, not recruiting |
NCT04696432 -
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
|
Phase 1 | |
Terminated |
NCT02361346 -
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04693676 -
A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma
|
Phase 1 | |
Recruiting |
NCT04655677 -
A Study of EXP039 Treatment in Subjects With r/r NHL Subjects
|
Phase 1 | |
Active, not recruiting |
NCT03000192 -
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
|
||
No longer available |
NCT02715843 -
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
|